BACKRepeated Low-Level Red-Light Therapy Device
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 1 August 2025]
We are inviting expressions of interest (EoI) for commercializing “Repeated Low-Level Red-Light Therapy Device” technology. The innovation is developed by Professor YAM Cheuk Sing, Professor of Department of Ophthalmology and Visual Sciences of The Chinese University of Hong Kong (CUHK Reference: 24/MED/1449).
The Technology
The AtroRed is a validated portable, user-friendly repeated low level red light (RLRL) therapy device tailored for safe use with low-concentration atropine. It aims to enhance the quality of myopia treatment through the improvements in capacity and reliability.This invention discloses the devices, system and methods for treating myopia, particularly in children.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
Repeated Low-Level Red-Light Therapy Device
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 1 August 2025]
We are inviting expressions of interest (EoI) for commercializing “Repeated Low-Level Red-Light Therapy Device” technology. The innovation is developed by Professor YAM Cheuk Sing, Professor of Department of Ophthalmology and Visual Sciences of The Chinese University of Hong Kong (CUHK Reference: 24/MED/1449).
The Technology
The AtroRed is a validated portable, user-friendly repeated low level red light (RLRL) therapy device tailored for safe use with low-concentration atropine. It aims to enhance the quality of myopia treatment through the improvements in capacity and reliability.This invention discloses the devices, system and methods for treating myopia, particularly in children.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.